Does abciximab improve the prognosis of diabetics after percutaneous coronary intervention?

Revista Espanola de Cardiologia

Volumn 55, Issue 8, 2002, Pages 810-815

  Hernández García, José Mária ^a   Domínguez Franco, Antonio ^a   Jiménez Navarro, Manuel F ^a   Alonso Briales, Juan H ^a   Curiel Balsera, Emilio ^a   Gómez Doblas, Juan J ^a   de Teresa Galván, Eduardo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Coronary angioplasty; Diabetes mellitus; Prognosis; Revascularization

Indexed keywords

ABCIXIMAB; GLYCERYL TRINITRATE; HEPARIN; INSULIN; ORAL ANTIDIABETIC AGENT; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; DEATH; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; FOLLOW UP; GROUPS BY AGE; GROUPS BY SEX; HEART INFARCTION; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HOSPITAL ADMISSION; HUMAN; ISCHEMIC HEART DISEASE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; POSTOPERATIVE CARE; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; THROMBUS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ANTAGONISM; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; RISK FACTOR; STATISTICAL ANALYSIS; TIME;

AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CHI-SQUARE DISTRIBUTION; CLINICAL TRIALS; CORONARY ANGIOGRAPHY; DATA INTERPRETATION, STATISTICAL; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 0036667502     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(02)76709-2     Document Type: Article

References (32)

1. Gowda MS, Vaceck JL, Hallas D. One year outcomes of diabetics versus nondiabetics patients with non-Q-wave acute myocardial infarction treated with percutaneous transluminal coronary angioplasty. Am J Cardiol 1998;81:1067-71.
2. Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, Lieberman HA, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995;91:979-89.
3. Barsness GW, Peterson ED, Ohman EM. Relationship between diabetes mellitus and long term survival after coronary by-pass and angioplasty. Circulation 1997;96:2551-6.
4. Haffner SM, Lehto S, Ronnemaa T, Pyolara K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetics subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
5. Carrozza JP, Ho KK, Neimann D, Kuntz RE, Cutlip DE. Diabetes mellitus is associated with adverse 6 month angiographic and clinical outcome following coronary stenting. Circulation 1998,98:I-79.
6. Marso SP, Ellis SG, Bhatt DL, Sapp SK, Emannuelsson H, Topol EJ. The stenting in diabetics debate: insight from the large GUSTO-IIb experience with extended follow-up. Circulation 1998;98:I-78.
7. Topol EJ, Califf RM, Weisman HF. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six month. The EPIC investigators. Lancet 1994;343:881-6.
8. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
9. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997; 349:1429-35.
10. Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleiman NS, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus. Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) Diabetic Substudy. Circulation 1999;100:2477-84.
11. Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer J, et al. Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 1999;341:319-27.
12. Iwase E, Tawata M, Aida K. A cross-sectional evaluation of spontaneous platelet aggregation in relation to complications in patients with type 2 diabetes mellitus. Metabolism 1998;47:699-705.
13. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35:922-8.
14. Kuntz RE. Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy. The Diabetes-Percutaneous transluminal coronary angioplasty dilemma. Circulation 1999;99:847-51.
15. Ostermann H, Van de Loo J. Factors of the hemostatic system in diabetic patients. A survey of controlled studies. Haemostasis 1986;16:386-416.
16. Stout RW. Insulin and atheroma: 20-years perspective. Diabetes Care 1990;13:631-54.
17. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. The National Heart, Lung and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1986;94:1818-25.
18. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzki M, Dirschinger J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866-73.
19. Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993;118:344-9.
20. Abizaid A, Kornowski R, Mintz G, Hong MK, Mehran R. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32:584-9.
21. O'Keefe JH, Blacksone EH, Sogeaut P, Mc Allister BD. The optimal mode of coronary revascularization for diabetics. Eur Heart J 1998;19:1696-703.
22. Pascual DA, Valdés M, García F, Garzón A, González J, García A, et al. Influencia de la diabetes mellitus en los resultados clínicos tardíos de la revascularización coronaria con stents. Rev Esp Cardiol 2001;54:261-8.
23. Alonso J. Diabetes mellitus y revascularización coronaria. La controversia continúa. Rev Esp Cardiol 2001;54:255-8.
24. Bhatt DL, Marso SP, Lincoff M, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35:922-8.
25. Alfonso F, Rodríguez P, Philips P, Goicolea J, Hernández R, Pérez-Vizcayno MJ, et al. Clinical and angiographic implications of coronary stenting in thrombus containing lesions. J Am Coll Cardiol 1997;29:725-33.
26. Musa Khan M, Ellis SG, Aguirre FV, Weisman HF, Wildermann NM, Califf RM, et al. Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. J Am Coll Cardiol 1998;31:31-6.
27. Ellis SG, Lincoff MD, Miller D, Tcheng JE, Kleiman NS, Kereiakes D, et al. Reduction in complications of angioplasty with Abciximab occurs largely independently of baseline lesion morphology. J Am Coll Cardiol 1998;32:1619-23.
28. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, et al. Effect of glycoprotein IIb-IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695-701.
29. Kornowski R, Mintz G, Kent KM, Pichard AD, Satler LF, Bucher TA, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hiperplasia. Circulation 1997;95:1366-9.
30. The ERASER investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation 1999;100:799-806.
31. King III S, Mahmed E. Will blockin the platelet save the diabetic? Circulation 1999;100:2466-8.
32. 3) mediates platelet adhesion to the luminal aspect of endothelial cells.